Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting

Comparison of Cabazitaxel/Prednisone Alone or in Combination With Custirsen for 2nd Line Chemotherapy in Prostate Cancer (AFFINITY)

This study has been completed.
Information provided by (Responsible Party):
OncoGenex Technologies Identifier:
First received: April 9, 2012
Last updated: October 11, 2016
Last verified: October 2016
No Study Results Posted on for this Study
  Study Status: This study has been completed.
  Study Completion Date: July 2016
  Primary Completion Date: July 2016 (Final data collection date for primary outcome measure)
  Certification or Request for Extension to Delay Results Received: October 7, 2016